Graham et al Haupt HA, Rovere GD. 1984. Anabolic steroids: a review of the literature. Am J Sports Med, 12:469–84. Healy ML, Gibney J, Russell-Jones DL, et al. 2003. High dose growth hormone exerts an anabolic effect at rest and during exercise in endur- ance-trained athletes. J Clin Endocrinol Metab, 11:5221–6. Healy ML, Gibney J, Pentecost C, et al. 2006. Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab, 9:320–7. Herrmann C. 1997. International experiences with the Hospital Anxiety and Depression Scale, a review of validation data and clinical results. J Psychosom Res, 42:17–41. Horber FF, Haymond MW. 1990. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest, 86:265–72. Iranmanesh A, Lizarralde G, Velduis JD. 1991. Age and relative adiposity are speciﬁc negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab, 73:1081–8. Irving BA, Patrie JT, Anderson SM, et al. 2004. The effects of time fol- lowing acute growth hormone administration on metabolic and power output measures during acute exercise. J Clin Endocrinol Metab, 89:4298–305. Janson C, Bjornsson E, Hetta J, et al. 1994. Anxiety and depression in relation to respiratory symptoms and asthma. Am J Respir Crit Care Med, 149:930–4. Jenkins PJ. 2001. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res, 11:71–7. Johannsson G, Grimby G, Sunnerhagen KS, et al. 1997. Two years of growth hormone (GH) treatment increases isometric and isokinetic muscle strength in GH-deﬁcient adults. JClin Endocrinol Metab, 82:2877–84. Kaminer Y, Robbins DR. 1989. Insulin misuse: a review of an over-looked psychiatric problem. Psychosomatics, 30:19–24. Karakula H, Grzywa A, Spila B, et al 1996. Use of Hospital Anxiety and Depression Scale in psychosomatic disorders. Psychiatr Pol, 30:653–67. Kimball SR, Vary TC, Jefferson LS. 1994. Regulation of protein synthesis by insulin. Ann Rev Physiol, 56:321–48. Konrad C, Schupfer G, Wietlisbach M, et al. 1998. Insulin as an anabolic: hypoglycaemia in the bodybuilding world. Anaesthesiol Intensivmed Schmerzther, 33:461–3. Kovacs M, Goldston D, Obrosky DS, et al. 1997. Psychiatric disorders in youths with IDDM: rates and risk factors. Diabetes Care, 20:36–44. Lange KH, Larsson B, Flyvberg A, et al. 2002a. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab, 87:4966–75. Lange KH, Andersen JL, Beyer N, et al. 2002b. GH admin changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab, 87:513–23. Le Roith D, Scavo L, Butler A. 2001. What is the role of circulating IGF-I? Trends Endocrinol Metab, 12:48–52. Lim VS, Yarasheski KE, Crowley JR, et al. 2003. Insulin is protein-anabolic in chronic renal failure patients. J Am Soc Nephrol, 14:2297–304. Liu W, Thomas SG, Asa SL, et al. 2003. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab, 88:5490–6. Lustman PJ, Grifﬁth LS, Clouse RE, et al. 1997. Effects of nortriptyline on depression and glycemic control in diabetes. Psychosom Med, 59:241–50. Mahajan T, Crown A, Checkley S, et al. 2004. Atypical depression in growth hormone deﬁcient adults, and the beneﬁcial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol, 151:325–32. 596 Martin CR, Lewin RJ, Thompson DR. 2003. A conﬁrmatory factor analysis of the Hospital Anxiety and Depression Scale in coronary care patients following acute myocardial infarction. Psychiatry Res, 120:85–94. Mauras N, Haymond MW. 2005. Are the metabolic effects of GH and IGF-I separable. Growth Horm IGF Res, 15:19–27. McGauley GA. 1989. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deﬁciency. Acta Paediatr Scand, 356:70–2. McMillan CV, Bradley C, Giannoulis M, et al. 2003. Preliminary develop- ment of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL. Health Qual Life Outcomes, 1:51. Melmed S. 2006. Medical progress: Acromegaly. N Engl J Med, 14:2558–73. Milani D, Carmichael JD, Welkowitz J, et al. 2004. Variability and reli- ability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab, 89:2271–4. Morris AD, Boyle DI, McMahon AD, et al. 1997. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulindependent diabetes mellitus. Lancet, 350:1505–10. Nørrelund H, Nair KS, Nielsen S, et al. 2003. The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab, 88:4371–8. Odie ELA. 1968. Insulin habituation and psychopathy. BMJ, 2:346. O’Reilly KE, Rojo F, She QB, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res, 66:1500–8. Pagonis TA, Angelopoulos NV, Koukoulis GN, et al. 2006a. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur Psychiatry, 21:563–9. Pagonis TA, Angelopoulos NV, Koukoulis GN, et al. 2006b. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlates to the severity of abuse. Eur Psychiatry, 21:551–62. Papadakis MA, Grady D, Black D, et al. 1996. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med, 124:708–16. Papazisis G, Kouvelas D, Mastrogianni A, et al. 2007. Anabolic androgenic steroid abuse and mood disorder: a case report. Int J Neuropsycho- pharmacol, 10:291–3. Pope HG Jr, Katz DL, Hudson JI. 1993. Anorexia nervosa and “reverse anorexia” among 108 male bodybuilders. Compr Psychiatry, 34:406–9. Potter J, Clarke P, Gale EA, et al. 1982. Insulininduced hypoglycaemia in an accident and emergency department: the tip of an iceberg? BMJ, 285:1182–90. Powrie JK, Bassett EE, Rosen T, et al. 2007. Detection of growth hormone abuse in sport. Growth Horm IGF Res, 17:220–6. Rennie MJ. 2003. Claims for the anabolic effect of growth hormone. A case for the Emperor’s new clothes. Br J Sports Med, 37:100–5. Retsas S. 1972. Insulin abuse by a drug addict. BMJ, 4:792–3. Rich JD, Dickinson BP, Merriman NA, et al. 1998. Insulin use by body- builders. JAMA, 279:1613. Riva G, Molinari E. 1995. Body image and social attitude in growth- hormone-deﬁcient adults. Percept Mot Skills, 80:1083–8. Ruckzika L, Wettstein A, Kaegi H. 1935. Sexual hormone VIII Darstel- lung von Testosterone unter Anwendung gemischter Ester. Helv Chim Acta, 18:1478. Rudman D, Feller AG, Nagraj HS, et al. 1990. Effect of human growth hormone in men over 60 years old. N Engl J Med, 323:1–6. Rudman D, Feller AG, Cohn L, et al. 1991. Effect of human growth hormone on body composition in elderly men. Horm Res, 36:73–81. Sato Y, Hayamizu S, Yamamoto C, et al. 1986. Improved insulin sensi- tivity in carbohydrate and lipid metabolism after physical training. Int J Sports Med, 7:307–10. Therapeutics and Clinical Risk Management 2008:4(3)